<DOC>
	<DOCNO>NCT00967759</DOCNO>
	<brief_summary>The primary outcome study evaluate clinical efficacy dose fixed combination drug , composes , isolate , regard respiratory symptom improvement superior air passage acute affection child 2 6 year old .</brief_summary>
	<brief_title>Study Comparing 3 Formulations Evaluate Efficacy Safety Inflammatory Symptoms Upper Respiratory Tract , Children Between 2 6 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Common Cold</mesh_term>
	<criteria>1 . Patients 2 6 year old , accord dosage information provide product package insert . 2 . Patient relative available observation symptom night . 3 . Patients acute symptom air passages jeopardize , initiate , least , 24 hour patient inclusion protocol , , 3 day patient inclusion . 4 . Patients face least 7 point score addition general symptom ( rhinorrhea , sneeze , itching , nose obstruction cough ) . 5 . At least two symptom must moderate scale , specific evaluation . 6 . Presence fluid and/or sputum verify rhinoscopy . 1 . Children young 2 year old weight and/or height percentual inferior 10 . 2 . Children corporal weight superior 30Kg . 3 . Suggestive sign superior air passages bacterial infection rhinoscopy , otoscopy oropharingoscopy . 4 . Chronic oral breath 6 month history . 5 . Presence degree II III nasal septal deviation ( region nasal fossa ) and/or presence nasal polyp condition determine nasal obstruction . 6 . Patients chronic medication treatment allergy . 7 . Patients asthma clinical history confirm ( diagnose ) . 8 . Personal preceding nasal surgery opinion investigator influence resistance air nose flow . 9 . Children old 5 year old registered school . 10 . Children don´t vaccination notebook . 11 . Patient use prohibited medication , establish period V0 Randomization Visit ( See Picture 1 ) . 12 . Hypersensitive history study drug component . 13 . Patient participate , last 12 month , study protocol ( accord Resolution 251 , date August , 7th 1997 , item III , subitem J , `` Investigator Responsibility '' , recommend person subject clinical study new project elapse 1 ( one ) year previous study participation , unless direct benefit study patient ) . 14 . Relatives sponsor´s study site´s employee . 15 . Patients gastroesofagic reflux disease . 16 . Presence psychiatry disease . 17 . Presence mental disorder etiology . 18 . Renal hepatic insufficiency . 19 . Patient current evidence clinically significant disease , origin : hematopoietic , gastrointestinal , cardiovascular , hepatic , renal , neurological , endocrinological , psychiatric , self immune , pulmonary , preclude , accord investigator criterion , subject participation . 20 . Patients genetic disease . 21 . Any finding clinical observation ( anamneses physical evaluation ) understood investigator risk patient participation study . 22 . Any finding lab result investigator judge risk patient , consider participation study . 23 . Patients AST ALT level higher 20 % related upper normal limit ; total bilirubin increase 10 % related upper normal limit ; fast serum/blood glucose &gt; 99mg/dl postprandial serum/blood glucose &gt; 140mg/dl ; Hb &lt; 10g/dl ou Hb &gt; 15 g/dl ; serum creatinine level 10 % upper limit ; serum potassium 3,5 mEq/L , upper 5,1 mEq/L ; serum sodium 136 mEq/L , upper 145 mEq/L . 24 . Presence hematogenous meliceric , purulent mucus purulent secretion , bulge malformation ( leporine lips nasolabial fissure surgically correct ) region nasal vestibule .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>common cold</keyword>
	<keyword>treatment</keyword>
	<keyword>inflammatory symptom superior air passage affection</keyword>
</DOC>